Fair Value Measurement (Quantitative Information About Recurring and Non-recurring Level 3 Fair Value Measurements) (Details) (USD $) In Millions, unless otherwise specified	9 Months Ended		3 Months Ended		9 Months Ended				9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014 SHP602 IPR&D	Jun. 30, 2014 SHP613	Sep. 30, 2014 Recurring Basis Contingent Consideration Payable Minimum	Sep. 30, 2014 Recurring Basis Contingent Consideration Payable Maximum	Sep. 30, 2014 Recurring Basis Contingent Consideration Payable Income approach (probability weighted discounted cash flow)	Sep. 30, 2014 Recurring Basis Contingent Consideration Receivable Income approach (probability weighted discounted cash flow)	Sep. 30, 2014 Recurring Basis Contingent Consideration Receivable Income approach (probability weighted discounted cash flow) Minimum	Sep. 30, 2014 Recurring Basis Contingent Consideration Receivable Income approach (probability weighted discounted cash flow) Maximum	Sep. 30, 2014 Nonrecurring Basis SHP602 IPR&D	Sep. 30, 2014 Nonrecurring Basis SHP613	Sep. 30, 2014 Nonrecurring Basis Income approach (discounted cash flow) SHP602 IPR&D	Sep. 30, 2014 Nonrecurring Basis Income approach (discounted cash flow) Minimum SHP602 IPR&D	Sep. 30, 2014 Nonrecurring Basis Income approach (discounted cash flow) Maximum SHP602 IPR&D
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Assets								$ 19.1			$ 0	$ 0
Liabilities							642.0
Fair Value Inputs
Probability weightings applied to different sales scenarios									10.00%	70.00%
Future forecast consideration receivable based on contractual terms with purchaser									15	120
Assumed market participant discount rate					0.80%	11.80%			8.00%	11.50%			11.30%
Cumulative probability of milestones being achieved					4.00%	95.00%
Periods in which milestones are expected to be achieved					2015	2030
Forecast quarterly royalties payable on net sales of relevant products					2.1	7.6
Probability of regulatory approval being obtained														11.00%	15.00%
Expected commercial launch date													2021
Impairment of intangible assets	$ 188.0	$ 19.9	$ 166.0	$ 22.0							$ 166.0	$ 22.0